Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Tsang Website

Kwong Yok Tsang, Ph.D.

Selected Publications

1)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
[Journal]
2)  Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol. Immunother. 63: 161-74, 2014.
[Journal]
3)  Cereda V, Vergati M, Huen N, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
Vaccine. 29: 4992-9, 2011.
[Journal]
4)  Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer Immunol. Immunother. 60: 197-206, 2011.
[Journal]
5)  Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clin. Cancer Res. 14: 1032-40, 2008.
[Journal]
6)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang K, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. [Epub ahead of print], 2014.
[Journal]
7)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-41, 2014.
[Journal]
8)  Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Kim Lyerly H, Schlom J, Guadagni F.
Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis.
J. Natl. Cancer Inst. 106, 2014.
[Journal]
9)  Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.
Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy.
J. Immunol. 192: 2622-33, 2014.
[Journal]
10)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. 63: 225-34, 2014.
[Journal]
11)  Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
Oncotarget. 5: 403-16, 2014.
[Journal]
12)  Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.
Therapeutic cancer vaccines.
Adv. Cancer Res. 121: 67-124, 2014.
[Journal]
13)  Hamilton DH, Huang B, Fernando RI, Tsang K, Palena C.
WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial-Mesenchymal Transition.
Cancer Res. [Epub ahead of print], 2014.
[Journal]
14)  Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL.
Prendergast G, Jaffee E, eds.
Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy.
Elsevier; 2013. In Press. [Book Chapter]
15)  Schlom J, Palena C, Gulley JL, Greiner JW, Tsang KY, Madan RA, Hodge JW.
Lattime E, Gerson SL, eds.
The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Third Edition.
Elsevier; 2013. In Press. [Book Chapter]
16)  Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR.
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Int. J. Cancer. 133: 624-36, 2013.
[Journal]
17)  Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Oncologist. 18: 821-2, 2013.
[Journal]
18)  Takai S, Schlom J, Tucker J, Tsang KY, Greiner JW.
Inhibition of TGF-ß1 Signaling Promotes Central Memory T Cell Differentiation.
J. Immunol. 191: 2299-307, 2013.
[Journal]
19)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang K, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
20)  Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
J. Immunol. 190: 6250-8, 2013.
[Journal]
21)  Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Int J Cancer. 133: 373-82, 2013.
[Journal]
22)  Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton DH, Huang B, Tucker JA, Tsang KY, Schlom J, Palena C.
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Clin Cancer Res. 18: 3868-79, 2012.
[Journal]
23)  Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J.
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood. 120: 3030-8, 2012.
[Journal]
24)  Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I.
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.
Proc. Natl. Acad. Sci. U.S.A. 109: E3597-603, 2012.
[Journal]
25)  Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY.
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.
Cancers (Basel). 4: 1333-48, 2012.
[Journal]
26)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
[Journal]
27)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. 15: 289-95, 2012.
[Journal]
28)  Tucker JA, Jochems C, Gulley JL, Schlom JW, Tsang KY.
Shifting the balance of cell-mediated immunity and suppression in human prostate cancer [review].
Cancers. 4: 1333-1348, 2012.
[Journal]
29)  Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D.
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Expert Opin Biol Ther. 11: 1409-18, 2011.
[Journal]
30)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
[Journal]
31)  Tsang KY, Gulley JL.
Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.
Asian J Androl. 13: 657-8, 2011.
[Journal]
32)  Whiteside TL, Gulley JL, Clay TM, Tsang KY.
Immunologic monitoring of cellular immune responses in cancer vaccine therapy.
J. Biomed. Biotechnol. 2011: 370374, 2011.
[Journal]
33)  Vergati M, Schlom J, Tsang KY.
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring.
J. Biomed. Biotechnol. 2011: 182413, 2011.
[Journal]
34)  Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, Nelson BH.
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
Clin. Cancer Res. 16: 4046-56, 2010.
[Journal]
35)  Litzinger MT, Foon KA, Tsang KY, Schlom J, Palena C.
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Leuk. Res. 34: 1351-7, 2010.
[Journal]
36)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
[Journal]
37)  Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY.
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer Immunol. Immunother. 59: 63-71, 2010.
[Journal]
38)  Correale P, Del Vecchio M, Remondo C, Rotundo M, Migali C, Ginanneschi C, Tsang K, Licchetta A, Mannucci S, Loiacona L, Tassone P, Francini G, Tagliaferri P.
Regulatory (FoxP3+) T cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo- or chemoimmunotherapy.
J Immunother. 33: 435-41, 2010.
[Journal]
39)  Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY.
Strategies for cancer vaccine development.
J. Biomed. Biotechnol. 2010, 2010.
[Journal]
40)  Litzinger MT, Foon KA, Sabzevari H, Tsang KY, Schlom J, Palena C.
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Cancer Immunol. Immunother. 58: 955-65, 2009.
[Journal]
41)  Remondo C, Cereda V, Mostböck S, Sabzevari H, Franzusoff A, Schlom J, Tsang KY.
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.
Vaccine. 27: 987-94, 2009.
[Journal]
42)  Kamrava M, Tsang K, Madan R, Kaushal A, Coleman CN, Gulley J.
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Clin Dev Immunol. 2009: 1-4, 2009.
[Journal]
43)  Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008.
[Journal]
44)  Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL.
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Clin. Cancer Res. 14: 5284-91, 2008.
[Journal]
45)  Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
J. Urol. 178: 1515-20, 2007.
[Journal]
46)  Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM, Pastan I, Schlom J, Tsang KY.
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
Int. J. Cancer. 121: 595-605, 2007.
[Journal]
47)  Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J.
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Clin. Cancer Res. 13: 2471-8, 2007.
[Journal]
48)  Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clin. Cancer Res. 12: 1260-9, 2006.
[Journal]
49)  Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW.
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clin. Cancer Res. 12: 1897-905, 2006.
[Journal]
50)  Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front. Biosci. 11: 788-803, 2006.
[Journal]
51)  Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector based cancer vaccines.
Curr. Pharm. Des. 12: 351-61, 2006.
[Journal]
52)  Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Clin. Cancer Res. 12: 4983-8, 2006.
[Journal]
53)  Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clin. Cancer Res. 11: 1597-607, 2005.
[Journal]
54)  Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
J. Urol. 174: 539-46, 2005.
[Journal]
55)  Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G.
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
J. Clin. Oncol. 23: 8950-8, 2005.
[Journal]
56)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin. Cancer Res. 11: 3353-62, 2005.
[Journal]
57)  Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G.
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
J. Immunol. 175: 820-8, 2005.
[Journal]
58)  Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY.
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Clin. Cancer Res. 11: 6342-51, 2005.
[Journal]
59)  Yang S, Tsang KY, Schlom J.
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Clin. Cancer Res. 11: 5603-15, 2005.
[Journal]
60)  Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
J. Clin. Oncol. 23: 720-31, 2005.
[Journal]
61)  Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood. 106: 3515-23, 2005.
[Journal]
62)  Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Clin. Cancer Res. 10: 2139-49, 2004.
[Journal]
63)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Dev Biol (Basel). 116: 27-47, 2004.
[Journal]
64)  Palena C, Zhu M, Schlom J, Tsang KY.
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Blood. 104: 192-9, 2004.
[Journal]
65)  Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW.
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
Cancer Res. 64: 7985-94, 2004.
[Journal]
66)  Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY.
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
J. Immunol. Methods. 279: 183-92, 2003.
[Journal]
67)  Palena C, Schlom J, Tsang KY.
Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide.
Clin. Cancer Res. 9: 1616-27, 2003.
[Journal]
68)  Palena C, Arlen P, Zeytin H, Greiner JW, Schlom J, Tsang KY.
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine. 24: 128-42, 2003.
[Journal]
69)  Hodge JW, Tsang KY, Poole DJ, Schlom J.
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecol. Oncol. 88: S97-104; discussion S110-3, 2003.
[Journal]
70)  Arlen PM, Gulley JL, Tsang K, Schlom J.
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Expert Rev Vaccines. 2: 483-93, 2003.
[Journal]
71)  Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C.
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer Res. 62: 5049-57, 2002.
[Journal]
72)  Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clin. Cancer Res. 8: 41-53, 2002.
[Journal]
73)  Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Cancer Res. 61: 3725-34, 2001.
[Journal]
74)  Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW.
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I.
J. Immunol. Methods. 248: 183-94, 2001.
[Journal]
75)  Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G, Francini G.
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.
Eur. J. Cancer. 37: 892-902, 2001.
[Journal]
76)  Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J.
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer Res. 61: 7568-76, 2001.
[Journal]
77)  von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
Clin. Cancer Res. 7: 1181-91, 2001.
[Journal]
78)  Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Clin. Cancer Res. 6: 1632-8, 2000.
[Journal]
79)  Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J.
Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
Int. J. Cancer. 85: 829-38, 2000.
[Journal]
80)  Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J.
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
J. Clin. Oncol. 18: 3964-73, 2000.
[Journal]
81)  Cole DJ, Baron PL, O'Brien P, Reed CE, Schlom J, Tsang KY.
Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost.
Clin Lung Cancer. 1: 227-9, 2000.
[Journal]
82)  von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM.
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
Clin. Cancer Res. 6: 2219-28, 2000.
[Journal]
83)  Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY.
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Clin. Cancer Res. 6: 24-33, 2000.
[Journal]
84)  Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Cancer Immunol. Immunother. 49: 517-29, 2000.
[Journal]
85)  Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J.
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
J. Clin. Oncol. 17: 332-7, 1999.
[Journal]
86)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Strategies in the development of recombinant vaccines for colon cancer.
Semin. Oncol. 26: 672-82, 1999.
[Journal]
87)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Cancer vaccine development.
Expert Opin Investig Drugs. 7: 1439-52, 1998.
[Journal]
88)  Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY.
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
J. Immunol. 161: 3186-94, 1998.
[Journal]
89)  Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Cancer Res. 57: 4570-7, 1997.
[Journal]
90)  Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
J. Natl. Cancer Inst. 89: 293-300, 1997.
[Journal]
91)  Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J.
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Clin. Cancer Res. 3: 2439-49, 1997.
[Journal]
92)  Abrams SI, Hand PH, Tsang KY, Schlom J.
Mutant ras epitopes as targets for cancer vaccines.
Semin. Oncol. 23: 118-34, 1996.
[Journal]
93)  Cole DJ, Wilson MC, Baron PL, O'Brien P, Reed C, Tsang KY, Schlom J.
Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.
Hum. Gene Ther. 7: 1381-94, 1996.
[Journal]
94)  Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM.
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.
Breast Cancer Res. Treat. 38: 27-39, 1996.
[Journal]
95)  Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
J. Natl. Cancer Inst. 87: 982-90, 1995.
[Journal]
96)  Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY.
Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Immunol. Lett. 47: 15-24, 1995.
[Journal]
97)  Yamaue H, Kashmiri SV, De Filippi R, Nieroda C, Yannelli JR, Tsang KY, Schlom J.
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
J Immunother Emphasis Tumor Immunol. 16: 262-74, 1994.
[Journal]
98)  Tsang KY, Kashmiri SV, De Filippi R, Qi CF, Calvo B, Shu L, Nieroda CA, Greiner JW, Schlom J.
A human T cell line engineered to secrete chimeric monoclonal antibody.
J. Immunother. 13: 143-52, 1993.
[Journal]
99)  Arlen M, Hollinshead AC, Tsang KY.
Identification and characterization of a colon tumor-associated antigen.
Ann. N. Y. Acad. Sci. 690: 374-5, 1993.
[Journal]
100)  Arlen M, Tsang KY.
Monoclonal antibodies and their role in modulation of the immune response.
J Surg Oncol. 54: 103-8, 1993.
[Journal]
101)  Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J.
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.
Immunol. Lett. 36: 179-85, 1993.
[Journal]
102)  Tsang KY, Finch MD, Primus FJ, Schlom J.
Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Cancer Immunol. Immunother. 34: 9-16, 1991.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.